Haemato AG
XETRA:HAEK
Intrinsic Value
Haemato AG engages in the pharmaceutical industry. [ Read More ]
The intrinsic value of one HAEK stock under the Base Case scenario is 21.48 EUR. Compared to the current market price of 21.4 EUR, Haemato AG is Fairly Valued.
Valuation Backtest
Haemato AG
Run backtest to discover the historical profit from buying and selling HAEK stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Haemato AG
Current Assets | 77.3m |
Cash & Short-Term Investments | 26.1m |
Receivables | 23.3m |
Other Current Assets | 27.9m |
Non-Current Assets | 106.1m |
Long-Term Investments | 10.9m |
PP&E | 3.8m |
Intangibles | 91.3m |
Other Non-Current Assets | 144k |
Current Liabilities | 31.4m |
Accounts Payable | 20.2m |
Accrued Liabilities | 766k |
Other Current Liabilities | 10.4m |
Non-Current Liabilities | 2.6m |
Long-Term Debt | 2.5m |
Other Non-Current Liabilities | 135k |
Earnings Waterfall
Haemato AG
Revenue
|
260.8m
EUR
|
Cost of Revenue
|
-241.1m
EUR
|
Gross Profit
|
19.7m
EUR
|
Operating Expenses
|
-10.6m
EUR
|
Operating Income
|
9.2m
EUR
|
Other Expenses
|
444.4k
EUR
|
Net Income
|
9.6m
EUR
|
Free Cash Flow Analysis
Haemato AG
HAEK Profitability Score
Profitability Due Diligence
Haemato AG's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
Score
Haemato AG's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
HAEK Solvency Score
Solvency Due Diligence
Haemato AG's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Score
Haemato AG's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HAEK Price Targets Summary
Haemato AG
According to Wall Street analysts, the average 1-year price target for HAEK is 34 EUR .
Shareholder Return
HAEK Price
Haemato AG
Average Annual Return | -19.08% |
Standard Deviation of Annual Returns | 18.12% |
Max Drawdown | -69% |
Market Capitalization | 111.5m EUR |
Shares Outstanding | 5 210 387 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Haemato AG engages in the pharmaceutical industry. The company is headquartered in Schoenefeld, Brandenburg. The company went IPO on 2012-03-26. The firm trades and patent-free and patent-protected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. The firm's main markets are Europe, North America and Japan. The company also imports medicines from within the European Economic Area in form of parallel imports and re-imports. The firm's subsidiaries are Haemato Pharm GmbH, Heamato Med GmbH, Castell Pharma BV, Sanate GmbH and Heamato Asia Co Ltd. Customers can order medicine through phone, fax and e-mail, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one HAEK stock under the Base Case scenario is 21.48 EUR.
Compared to the current market price of 21.4 EUR, Haemato AG is Fairly Valued.